Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Please Complain: FDA Needs GDUFA Meeting Comments, Presenters

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency officials indicate feedback is critical as generic drug user fee program enters its third year and applications go on the clock in earnest.

You may also be interested in...



Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes

U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.

Generic Exclusivity Awards Process Might Go Public

FDA wants to know whether 180-day exclusivity should be revealed up front; question is one of many on ANDA reviews to be considered at September public hearing.

Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree

Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel